Alvotech - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ALVO Nasdaq 2834 www.alvotech.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alvotech

Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors - Jun 11th, 2025 2:20 pm
Alvotech Meets Investors and Presents at the Goldman Sachs Global Healthcare Conference in Miami - Jun 6th, 2025 6:30 am
Alvotech Participates in the Goldman Sachs Global Healthcare Conference in Miami - Jun 6th, 2025 6:30 am
Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab) - Jun 5th, 2025 5:00 am
Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million - Jun 4th, 2025 8:29 pm
Alvotech intends to carry out a private placement of approximately 7.5 million SDRs and ordinary shares - Jun 4th, 2025 9:32 am
Alvotech Completes Acquisition of Xbrane R&D Organization and biosimilar candidate to Cimzia® - Jun 4th, 2025 5:45 am
Alvotech Meets Investors and Presents at the Jefferies Global Healthcare Conference 2025 in New York, NY - Jun 2nd, 2025 7:15 am
Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe - May 28th, 2025 4:15 am
Alvotech Appoints DNB Carnegie as Liquidity Provider on Nasdaq Stockholm - May 19th, 2025 1:15 am
Trading in Alvotech’s Shares on Nasdaq Stockholm Commences Today - May 19th, 2025 12:30 am
Alvotech Announces the Outcome of the Offering in Connection with the Company’s Listing on Nasdaq Stockholm - May 16th, 2025 11:52 am
There May Be Underlying Issues With The Quality Of Alvotech's (NASDAQ:ALVO) Earnings - May 15th, 2025 4:53 am
Analyst Estimates: Here's What Brokers Think Of Alvotech (NASDAQ:ALVO) After Its First-Quarter Report - May 10th, 2025 7:28 am
Alvotech Meets Investors and Participates in Fireside Chat At the BofA Securities Healthcare Conference 2025 in Las Vegas, Nevada - May 9th, 2025 6:00 am
Alvotech Publishes Prospectus in Connection with its Listing on Nasdaq Stockholm - May 8th, 2025 12:30 am
Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update - May 7th, 2025 2:45 pm
Exploring High Growth Tech Stocks In The US Market - May 7th, 2025 11:38 am
Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech’s Product Revenues in 2025 - May 7th, 2025 3:00 am
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab) - May 5th, 2025 5:49 am